Pfizer, Allergan End $160B Merger After New Inversion Regs
By Chelsea Naso · April 6, 2016, 7:01 AM EDT
Pfizer and Allergan called off their planned $160 billion combination Wednesday, marking an end to what would have been the largest so-called inversion transaction on record after the U.S. Department of...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login